Literature DB >> 24332811

APOE gene polymorphisms and susceptibility to Creutzfeldt-Jakob disease.

Yunfei Wei1, Yanyan Tang1, Wenwu He2, Zhanli Qu1, Jinming Zeng3, Chao Qin4.   

Abstract

Associations between apolipoprotein E (APOE) gene polymorphisms and Creutzfeldt-Jakob disease (CJD) have been reported, but the results from many of these studies are conflicting. To investigate the association between APOE polymorphisms and CJD risk, we performed a meta-analysis. We used odds ratios (OR) with 95% confidence intervals (CI) to assess the strength of the association. The frequency of putative risk alleles in control subjects was estimated with the Mantel-Haenszel method. Cochran's Q statistic and the inconsistency index (I(2)) were used to test heterogeneity. Egger's test and an inverted funnel plot were used to assess bias. Our study included 11 published case-control studies with APOE genotyping, involving a total of 1001 CJD patients and 1211 controls. Overall, the APOE 34 (OR 1.37, 95% CI: 1.09-1.72), and APOE 44 (OR 3.16, 95% CI: 1.37-7.26) genotypes and the APOE 4 (OR 1.41, 95% CI: 1.08-1.85) allele were associated with an increased risk of CJD, and the APOE 33 (OR 0.81, 95% CI: 0.67-0.97) genotype tended to protect against CJD. However, we did not find significant evidence supporting associations of the APOE 22 (OR 1.15, 95% CI: 0.45-2.93), APOE 23 (OR 0.84, 95% CI: 0.64-1.09), or APOE 24 (OR 1.40, 95% CI: 0.70-2.77) genotypes, nor the APOE 2 (OR 1.02, 95% CI: 0.73-1.42) or APOE 3 (OR 0.82, 95% CI: 0.65-1.02) alleles with CJD using a fixed-effects model. Our results support a genetic association between APOE polymorphisms and CJD.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  APOE; Apolipoprotein E; Creutzfeldt–Jakob disease; Meta-analysis; Polymorphism

Mesh:

Substances:

Year:  2013        PMID: 24332811     DOI: 10.1016/j.jocn.2013.07.019

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  4 in total

1.  Longitudinal clinical, neuropsychological, and neuroimaging characterization of a kindred with a 12-octapeptide repeat insertion in PRNP: the next generation.

Authors:  Ryan A Townley; Angelina J Polsinelli; Julie A Fields; Mary M Machulda; David T Jones; Jonathan Graff-Radford; Kejal M Kantarci; Val J Lowe; Rosa V Rademakers; Matt C Baker; Neeraj Kumar; Bradley F Boeve
Journal:  Neurocase       Date:  2020-06-30       Impact factor: 0.881

2.  The characterization of AD/PART co-pathology in CJD suggests independent pathogenic mechanisms and no cross-seeding between misfolded Aβ and prion proteins.

Authors:  Marcello Rossi; Hideaki Kai; Simone Baiardi; Anna Bartoletti-Stella; Benedetta Carlà; Corrado Zenesini; Sabina Capellari; Tetsuyuki Kitamoto; Piero Parchi
Journal:  Acta Neuropathol Commun       Date:  2019-04-08       Impact factor: 7.801

3.  Sporadic Creutzfeldt-Jakob Disease and Other Proteinopathies in Comorbidity.

Authors:  Eva Parobkova; Julie van der Zee; Lubina Dillen; Christine Van Broeckhoven; Robert Rusina; Radoslav Matej
Journal:  Front Neurol       Date:  2020-11-30       Impact factor: 4.003

Review 4.  The potential applications of Apolipoprotein E in personalized medicine.

Authors:  Sylvia Villeneuve; Diane Brisson; Natalie L Marchant; Daniel Gaudet
Journal:  Front Aging Neurosci       Date:  2014-07-08       Impact factor: 5.750

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.